European Psychiatry - Volume 33 - March 2016

520 / 812

S516 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
Aims To analyze the occurrence and clinical particularities of dif-
ferent types of interictal depression in epilepsy patients.
Methods One hundred and fourteen epilepsy patients with inter-
ictal depression were assessed with a clinical interview and
Hamilton depression and anxiety rating scales. Diagnostic criteria
of ICD-10 and of the International League Against Epilepsy (ILAE)
were used.
Results A total of 45.6% of patients met ILAE criteria of iner-
ictal dysforic disorder (IDD) with predominance of depressive
mood, irritability, fear and atypical pain. All patients had chronic
epilepsy with specific epileptic personality changes. Comorbid
adjustment disorders (depressive and anxious-depressive reac-
tions) were diagnosed in 27.2% of patients. The most frequent
trigger situations were: family problems, serious illness, unem-
ployment, financial difficulties. In more than half of patients were
registered specific personality changes whose severity was in
inverse ratio with trauma severity. A total of 18.4% of patients
met criteria of comorbid affective disorder (depressive and bipo-
lar) with some specific clinical traits due to personality changes. In
8.8% of patients, anticonvulsant-induced depression was observed;
it was clinically simple, resolved after offending medication with-
drawal.
Conclusions Observed depressive disorders were heteroge-
neous: comorbid or attributed to epilepsy or its treatment.
The most frequent condition was IDD. Specific personality
changes may contribute to higher susceptibility and develop-
ment of psychogenic depression. We emphasize the impor-
tance of treatment history (possibility of anticonvulsant-induced
depression).
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV522
Regulation of serum spadin
propeptide: An antidepressant
response probe
J. Mazella ∗ evader , M. Roulot , M. Borsotto , C. Heurteaux
Institut de pharmacologie moléculaire et cellulaire, CNRS–Life
science, Valbonne, France
∗ Corresponding author.
Objectives We previously discovered that spadin, a short ana-
logue of the propeptide (PE) released from the maturation of
sortilin, displays potent antidepressant properties. Since the PE
level can be measured in the blood, we aimed to investigate how
the PE serum concentration is regulated in mice. We wondered
whether the PE serum levels vary between healthy subjects and
patients with major depressive disorder (MDD).
Methods We developped a dosing method based on the
AlphaScreenTM technology (Perkin) which allow to selectively
detect both PE, spadin and metabolic products from these peptides
with a detection range of 1 ng/mL.
Results We found that insulin significantly up-regulated serum
PE concentration from 26.15 ± 2.63 to 41.43 ±6.27 nM (P = 0.0318).
Analysis during circadian cycle in mice revealed that the amount
of PE and its derivatives significantly varied during the cycle being
higher during the period of maximal activity (dark period). We also
measured serum insulin concentration between 1 and 7 pm and
observed a significant rise confirming the relationships between
insulin and PE concentration. We showed that the serum level of
PE is lower in depressive patients than in healthy non-psychiatric.
We observed that the weaker level of PE in depressive patients can
recover the level of healthy subjects after a chronic antidepressant
treatment.
Conclusions Dosing the serum level of PE could be a promising
approach for the diagnosis of depression and to determine the
remission of the disease.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV523
Treatment of mild to moderate major
depressive disorder with agomelatine
in patients with cardiovascular
disorders (national observational
multicenter study “pulse”)
V. Medvedev
Mosow, Russia
Introduction The urgency of depression treatment in patients
with cardiovascular diseases (CVD) is determined by the increasing
prevalence of affective disorders. For these patients, tolerance and
safety of antidepressants are of great importance.
Objective To obtain additional data on therapeutic efficacy and
tolerance of agomelatine in the treatment of mild to moderate
depressive disorders in cardiologic practice in Russia.
Methods Eight hundred and ninety-six adult patients with CVD
(86.5% arterial hypertension, 29.5% stable angina, 16% myocardial
infarction, 23.6% conduction disturbances, 17.6% chronic heart-
failure) were treated with agomelatine 25-50mg for 12 weeks.
Depression and anxiety symptoms were evaluated via Hospital
Anxiety and Depression Scale (HADS), Clinical Global Impression
(CGI-S and CGI-I), Visual Analog Scale (VAS), Spielberger Anxiety
Scale (SAS), Whitely Hypochondria Index (WHI) and quality of life
questionnaire (SF-36). Safety and tolerance were also monitored
according to the summary of product characteristics recommen-
dations.
Results HADS scores decreased throughout the study and severe
anxiety rate decreased from 95.9% to 15%. After 12 weeks of
treatment, remission (HADS < 7) rate was 84.6%. Subjective assess-
ment of patient health significantly improved (P < 0.00001). WHI
decreased significantly (P < 0.00001). Physical and mental health
significantly improved (P < 0.00001). Heart rate and blood pressure
decreased. Treatment acceptability was considered “excellent” by
82% of doctors and 75% of patients.
Conclusion Agomelatine significantly improved depressive
symptoms, anxiety and hypochondria in depressed patients with
CVD and demonstrated good tolerance. This suggests the possibil-
ity of wide and safe use of agomelatine for treatment of depression
in patients with CVD.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV524
Premorbid temperament as a
predictor for remission in depression
J. Miettunen ∗ arttila Rautio oivainen
S. Keinänen-Kiukaanniemi la-Mursula uvinen
M. Timonen
1 Oulu, Finland
2 University of Oulu, Center for Life Course Epidemiology and Systems
Medicine, Oulu, Finland
3 Verve Rehabilitation, Oulu, Finland
∗ Corresponding author.
Introduction Personality traits have been associated with risk for
depressive disorders. Studies with premorbid measures on person-
ality are uncommon.
Objective Estimate effect of premorbid personality as a predictor
for remission in depressive disorders.
Aim To study premorbid personality as a predictor for remission
in depression in a population based sample.